Prime Minister Shri Narendra Modi launches Nationwide HPV Vaccination Campaign and Development Projects Worth ₹17,000 Crore in Ajmer, Rajasthan

I have sufficient Tier 1/2 facts. Writing the note now.

Prime Minister Launches Nationwide HPV Vaccination Drive — Ajmer, Rajasthan

1. At a Glance

Nationwide Human Papillomavirus (HPV) vaccination campaign launched by PM Modi from Ajmer, Rajasthan, targeting 14-year-old girls as India's flagship intervention against cervical cancer [S1].
Vaccination is voluntary, free-of-cost, single-dose, administered after consent at Government Health Facilities [S1].
UPSC relevance: intersects GS-II (health policy, women & child welfare) and GS-III (S&T, public health interventions) and links to WHO 90-70-90 cervical cancer elimination targets [S4].

2. Why in the News

Launched on 28 February 2026 from Ajmer, Rajasthan, by Prime Minister Narendra Modi; Union Health Minister J.P. Nadda present [S1][S2].
Frames the rollout as a "new era of sensitivity in women's health" alongside clean fuel, sanitation and nutrition schemes [S1].

3. Background & Evolution

2008: HPV vaccine first available in India (private market) [S4].
2020: World Health Assembly adopted global strategy to eliminate cervical cancer; India a signatory among 194 countries [S4].
Feb 2024 Interim Budget: FM Nirmala Sitharaman announced HPV vaccination for girls aged 9–14 under "Nari Shakti" focus [S3].
2022: India's indigenous quadrivalent vaccine CERVAVAC (Serum Institute of India) received DCGI approval; first indigenous HPV vaccine [S5].
28 Feb 2026: Nationwide rollout formally launched from Ajmer [S1].

4. Core Static Facts

Implementing ministry: Ministry of Health and Family Welfare (MoHFW) [S1].
Target cohort: girls who have completed 14 years but not 15 years; annual cohort ≈ 1.2 crore (RGI 2021 estimates) [S2].
Schedule: Single dose, aligned with WHO SAGE recommendation [S2].
Vaccine in national programme: Gardasil-4 (quadrivalent — HPV types 6, 11, 16, 18) per current MoHFW briefing [S2]; indigenous CERVAVAC also part of India's HPV portfolio [S5].
Delivery channel: Government Health Facilities; integrated with Universal Immunization Programme (UIP) and Mission Indradhanush framework [S4].
Disease burden: India accounts for ~1.2 lakh new cervical cancer cases and ~80,000 deaths annually (WHO GLOBOCAN 2022) [S2][S6].
Vaccine efficacy: 93–100% against vaccine-covered HPV types [S2].

5. Multi-Dimensional Analysis

Social / Gender - Cervical cancer is the 2nd most common cancer in Indian women; vaccination addresses gendered health inequity [S2][S6]. - Voluntary + consent-based design respects bodily autonomy and parental consent norms [S1].

Scientific / Technological - WHO SAGE (2022) endorsed single-dose schedule as comparably efficacious to multi-dose; India's adoption signals evidence-based policy convergence [S2][S4]. - CERVAVAC reduces import dependency; supports Atmanirbhar Bharat in biologics [S5].

Administrative / Federal - States like Punjab, Sikkim, Karnataka, Tamil Nadu ran prior school-based pilots, informing national design [S4]. - Delivery through government facilities (not exclusively schools) accommodates out-of-school girls [S1].

Geopolitical / Strategic Health - Aligns India with WHO Global Strategy to Eliminate Cervical Cancer (2020) — 90% HPV vaccination of girls by 15, 70% screening, 90% treatment by 2030 [S4]. - Projected impact: ~1.06 crore lives saved by 2120 if 90-70-90 met [S4].

6. Recent Developments (last 12–18 months)

Feb 2024: Interim Union Budget announced HPV vaccination for 9–14 year girls [S3].
2024–25: State-level school-based drives in Sikkim, Punjab, Karnataka, Tamil Nadu [S4].
28 Feb 2026: Nationwide launch from Ajmer [S1].
Post-launch: Union Health Minister J.P. Nadda reaffirmed India's commitment at WHO HQ briefing [S6].

7. Prelims Hooks

HPV vaccination drive launched from Ajmer, Rajasthan on 28 February 2026 [S1].
Target age: girls who have completed 14 years but not 15 [S2].
Schedule: Single dose, aligned with WHO SAGE [S2].
Vaccine: Gardasil-4 (quadrivalent: HPV 6, 11, 16, 18) used in national programme [S2].
CERVAVAC — first indigenous HPV vaccine, by Serum Institute of India, DCGI-approved 2022 [S5].
Annual cohort ≈ 1.2 crore girls (RGI 2021) [S2].
WHO target year for cervical cancer elimination: 2030; incidence threshold <4 per 100,000 women [S4].
WHO 90-70-90: 90% vaccination, 70% screening, 90% treatment [S4].
Cervical cancer is the 2nd most common cancer among Indian women [S2].
India: ~1.2 lakh new cases & ~80,000 deaths/year (GLOBOCAN 2022) [S2].
Cervical cancer elimination global strategy adopted by World Health Assembly 2020 [S4].
Implementing ministry: MoHFW (not Women & Child Development) [S1].
HPV vaccination integrated under Universal Immunization Programme (UIP) [S4].
Programme is voluntary and requires consent [S1].
HPV vaccines are 93–100% effective vs covered HPV types [S2].

8. Mains Relevance

GS-II — Issues relating to development & management of Social Sector/Services (Health); Welfare schemes for vulnerable sections (women).
GS-III — Science & Technology indigenisation (CERVAVAC).
Probable stems: 1. "India's HPV vaccination rollout is as much about gender equity as about public health. Discuss." 2. "Examine the role of indigenous vaccine development (e.g., CERVAVAC) in achieving WHO's cervical cancer elimination targets by 2030." 3. "Single-dose HPV schedules represent a paradigm shift in immunization policy. Critically evaluate India's adoption."

9. Related Topics to Study Next

Universal Immunization Programme (UIP) — host architecture for HPV rollout.
Mission Indradhanush / Intensified Mission Indradhanush (IMI 5.0) — coverage drive synergy.
Ayushman Bharat — Health & Wellness Centres / PMJAY — screening & treatment linkage.
WHO Global Strategy on Cervical Cancer Elimination (2020) — international target alignment.
National Cancer Control Programme — broader oncology policy.
CERVAVAC & Serum Institute of India — biotech self-reliance.
Beti Bachao Beti Padhao / POSHAN Abhiyaan — adolescent girl welfare overlap.
Drugs Controller General of India (DCGI) & CDSCO — regulatory pathway.

10. Common Errors / Trap Areas

Wrong ministry: It is MoHFW, not Ministry of Women & Child Development.
Schedule confusion: India is using single-dose, not the older 2-/3-dose schedule.
Vaccine confusion: CERVAVAC is indigenous (SII) but the launch briefing cites Gardasil-4 as the programme vaccine — both are quadrivalent; do not conflate with Gardasil-9 (nonavalent).
Age band: Budget 2024 said 9–14; the launched campaign targets specifically 14-year-olds (one-year cohort) — easy MCQ trap.
Target year: WHO elimination milestone is 2030 (90-70-90), but full elimination in India modelled by ~2062 — distinct numbers.

11. Sources

[S1] Prime Minister Shri Narendra Modi Launches Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer, Rajasthan — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233906 — (tier: 1)
[S2] Cervical Cancer Vaccination Campaign Launched — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2234009 — (tier: 1)
[S3] 'Nari Shakti' Takes Center Stage; Union FM Announces Vaccination to Prevent Cervical Cancer (Interim Budget 2024) — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2001172 — (tier: 1)
[S4] Elimination Planning Tool: Advancing Towards Cervical Cancer Elimination — India (IARC/WHO) — https://gco.iarc.who.int/media/elimination_tool/factsheets/356-IND-india.pdf — (tier: 2)
[S5] PM to Launch Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer Tomorrow (curtain-raiser) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233632 — (tier: 1)
[S6] Union Minister Nadda Virtually Addresses Press Briefing at WHO HQ; Reaffirms India's Commitment to Eliminating Cervical Cancer — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235710 — (tier: 1)